000566 海南海药
已收盘 11-20 15:00:00
资讯
新帖
简况
股市必读:海南海药新发布《关于收到基金分配款暨基金清算的公告》
证券之星 · 11-09
股市必读:海南海药新发布《关于收到基金分配款暨基金清算的公告》
股市必读:海南海药新发布《关于收到基金分配款暨基金清算的公告》
证券之星 · 11-06
股市必读:海南海药新发布《关于收到基金分配款暨基金清算的公告》
海南海药(000566)2026年三季报简析:净利润同比下降42.49%,三费占比上升明显
证券之星 · 10-28
海南海药(000566)2026年三季报简析:净利润同比下降42.49%,三费占比上升明显
海南海药(000566)披露2026年三季度报告,10月27日股价下跌4.06%
证券之星 · 10-27
海南海药(000566)披露2026年三季度报告,10月27日股价下跌4.06%
海南海药(000566)9月30日股东户数14.12万户,较上期增加11.48%
证券之星 · 10-27
海南海药(000566)9月30日股东户数14.12万户,较上期增加11.48%
图解海南海药三季报:第三季度单季净利润同比下降58.54%
证券之星 · 10-27
图解海南海药三季报:第三季度单季净利润同比下降58.54%
海南海药:氟非尼酮胶囊III期临床研究正在积极有序推进
证券之星 · 10-23
海南海药:氟非尼酮胶囊III期临床研究正在积极有序推进
海南海药:相关技术指导原则的制定有助于进一步规范慢性乙型肝炎肝纤维化治疗药物的临床试验设计与评价标准
证券之星 · 10-23
海南海药:相关技术指导原则的制定有助于进一步规范慢性乙型肝炎肝纤维化治疗药物的临床试验设计与评价标准
海南海药:氟非尼酮进展情况请以CDE官网公示信息为准
证券之星 · 10-23
海南海药:氟非尼酮进展情况请以CDE官网公示信息为准
海南海药:存款利率不低于央行同期同类存款利率
证券之星 · 10-23
海南海药:存款利率不低于央行同期同类存款利率
海南海药:积极寻找转型发展,把改革调整作为破解困局的关键举措
证券之星 · 10-23
海南海药:积极寻找转型发展,把改革调整作为破解困局的关键举措
海南海药(000566)10月9日主力资金净买入890.45万元
证券之星 · 10-12
海南海药(000566)10月9日主力资金净买入890.45万元
股市必读:海南海药新发布《关于子公司获得注射用硫酸艾沙康唑药品注册批件的公告》
证券之星 · 10-12
股市必读:海南海药新发布《关于子公司获得注射用硫酸艾沙康唑药品注册批件的公告》
海南海药最新公告:子公司获注射用硫酸艾沙康唑药品注册批件
证券之星 · 10-09
海南海药最新公告:子公司获注射用硫酸艾沙康唑药品注册批件
海南海药(000566)9月23日主力资金净卖出2017.26万元
证券之星 · 09-24
海南海药(000566)9月23日主力资金净卖出2017.26万元
异动快报:海南海药(000566)9月21日10点54分触及涨停板
证券之星 · 09-21
异动快报:海南海药(000566)9月21日10点54分触及涨停板
海南海药最新公告:销售代理合同纠纷案原告撤诉
证券之星 · 09-16
海南海药最新公告:销售代理合同纠纷案原告撤诉
海南海药:氟非尼酮胶囊正在开展III期临床研究
证券之星 · 09-11
海南海药:氟非尼酮胶囊正在开展III期临床研究
海南海药:紧盯创新药核心突破
证券之星 · 09-11
海南海药:紧盯创新药核心突破
海南海药:符合资本化条件的研发项目按会计准则资本化
证券之星 · 09-11
海南海药:符合资本化条件的研发项目按会计准则资本化
加载更多
公司概况
公司名称:
海南海药股份有限公司
所属行业:
医药制造业
上市日期:
1994-05-25
主营业务:
海南海药股份有限公司的主营业务是药品研发、生产和销售。公司的主要产品是抗生素系列、胃肠道用药系列、抗肿瘤药系列、与制剂配套的原料药和中间体系列。
发行价格:
5.80
{"stockData":{"symbol":"000566","market":"SZ","secType":"STK","nameCN":"海南海药","latestPrice":3.45,"timestamp":1795158225000,"preClose":3.65,"halted":0,"volume":22773967,"delay":0,"changeRate":-0.0548,"floatShares":1297000000,"shares":1297000000,"eps":-0.4108,"marketStatus":"已收盘","change":-0.2,"latestTime":"11-20 15:00:00","open":3.6,"high":3.63,"low":3.45,"amount":80241300,"amplitude":0.0493,"askPrice":3.45,"askSize":1195,"bidPrice":3.44,"bidSize":1276,"shortable":0,"etf":0,"ttmEps":-0.4108,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1795397400000},"marketStatusCode":5,"adr":0,"adjPreClose":3.65,"symbolType":"stock","openAndCloseTimeList":[[1795138200000,1795145400000],[1795150800000,1795158000000]],"highLimit":4.02,"lowLimit":3.29,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1297365126,"isCdr":false,"pbRate":-17.84,"roa":"--","roe":"0.0%","epsLYR":-0.3314,"committee":-0.466841,"marketValue":4476000000,"turnoverRate":0.0176,"status":1,"floatMarketCap":4473000000},"requestUrl":"/m/hq/s/000566","defaultTab":"news","newsList":[{"id":"2682254998","title":"股市必读:海南海药新发布《关于收到基金分配款暨基金清算的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2682254998","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682254998?lang=zh_cn&edition=full","pubTime":"2026-11-09 02:10","pubTimestamp":1794161422,"startTime":"0","endTime":"0","summary":"公司公告汇总:海南海药收到烽康基金分配的鄂州鄂钢医院有限公司24%股权,评估值6,483万元,已完成股权登记变更,现持有鄂钢医院100%股权。公司公告汇总关于收到基金分配款暨基金清算的公告海南海药股份有限公司于2016年参与设立盐城海药烽康投资管理中心,实缴出资9,667万元,持股比例33.00%。因基金投资期届满,经全体合伙人协商,决定对可分配资产进行分配并启动清算注销程序。本次股权公允价值依据评估结果确定,具体会计处理以审计结果为准。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110900000612.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0239","BK0146","BK0070","BK0188","000566"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681058400","title":"股市必读:海南海药新发布《关于收到基金分配款暨基金清算的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2681058400","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681058400?lang=zh_cn&edition=full","pubTime":"2026-11-06 01:51","pubTimestamp":1793901072,"startTime":"0","endTime":"0","summary":"公司公告汇总:海南海药收到烽康基金分配的鄂钢医院24%股权,完成股权登记变更后持有鄂钢医院100%股权。公司公告汇总关于收到基金分配款暨基金清算的公告海南海药股份有限公司于2016年参与设立盐城海药烽康投资管理中心,实缴出资9,667万元,持股比例33.00%。公司近期收到烽康基金分配的鄂州鄂钢医院有限公司24%股权,该股权评估值为6,483万元,评估基准日为2026年3月31日,采用资产基础法评估,鄂钢医院股东全部权益评估价值为27,014.44万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110600002039.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0146","BK0239","BK0188","000566","BK0070","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678460392","title":"海南海药(000566)2026年三季报简析:净利润同比下降42.49%,三费占比上升明显","url":"https://stock-news.laohu8.com/highlight/detail?id=2678460392","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678460392?lang=zh_cn&edition=full","pubTime":"2026-10-28 20:19","pubTimestamp":1793189994,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理,近期海南海药发布2026年三季报。截至本报告期末,公司营业总收入4.81亿元,同比下降24.75%,归母净利润-3.45亿元,同比下降42.49%。按单季度数据看,第三季度营业总收入1.6亿元,同比下降15.49%,第三季度归母净利润-1.33亿元,同比下降58.54%。本报告期海南海药三费占比上升明显,财务费用、销售费用和管理费用总和占总营收同比增幅达38.89%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102800047059.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000566"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678817937","title":"海南海药(000566)披露2026年三季度报告,10月27日股价下跌4.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2678817937","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678817937?lang=zh_cn&edition=full","pubTime":"2026-10-27 19:08","pubTimestamp":1793099292,"startTime":"0","endTime":"0","summary":"截至2026年10月27日收盘,海南海药报收于4.02元,较前一交易日下跌4.06%,最新总市值为52.15亿元。该股当日开盘4.17元,最高4.19元,最低4.02元,成交额达1.32亿元,换手率为2.48%。海南海药于2026年10月27日披露《2026年三季度报告》。报告显示,本报告期营业收入为160,072,199.94元,同比下降15.49%;归属于上市公司股东的净利润为-133,173,072.34元,同比下降58.54%。年初至报告期末营业收入为481,333,431.04元,同比下降24.75%;归属于上市公司股东的净利润为-345,256,699.78元,同比下降42.49%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102700036309.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0070","000566","BK0060","BK0146","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678173718","title":"海南海药(000566)9月30日股东户数14.12万户,较上期增加11.48%","url":"https://stock-news.laohu8.com/highlight/detail?id=2678173718","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678173718?lang=zh_cn&edition=full","pubTime":"2026-10-27 18:37","pubTimestamp":1793097458,"startTime":"0","endTime":"0","summary":"证券之星消息,近日海南海药披露,截至2026年9月30日公司股东户数为14.12万户,较6月30日增加1.45万户,增幅为11.48%。在化学制药行业个股中,海南海药股东户数高于行业平均水平,截至9月30日,化学制药行业平均股东户数为3.84万户。从股价来看,2026年6月30日至2026年9月30日,海南海药区间跌幅为7.41%,在此期间股东户数增加1.45万户,增幅为11.48%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102700034593.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0146","BK0239","BK0060","000566","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678168113","title":"图解海南海药三季报:第三季度单季净利润同比下降58.54%","url":"https://stock-news.laohu8.com/highlight/detail?id=2678168113","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678168113?lang=zh_cn&edition=full","pubTime":"2026-10-27 02:30","pubTimestamp":1793039433,"startTime":"0","endTime":"0","summary":"证券之星消息,海南海药2026年三季报显示,前三季度公司主营收入4.81亿元,同比下降24.75%;归母净利润-3.45亿元,同比下降42.49%;扣非净利润-3.91亿元,同比下降43.54%;其中2026年第三季度,公司单季度主营收入1.6亿元,同比下降15.49%;单季度归母净利润-1.33亿元,同比下降58.54%;单季度扣非净利润-1.39亿元,同比下降51.04%;负债率104.55%,投资收益-808.89万元,财务费用1.31亿元,毛利率15.29%。财报数据概要请见下图:本文数据来源于海南海药2026年三季报,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102700003492.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000566"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677922709","title":"海南海药:氟非尼酮胶囊III期临床研究正在积极有序推进","url":"https://stock-news.laohu8.com/highlight/detail?id=2677922709","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677922709?lang=zh_cn&edition=full","pubTime":"2026-10-23 20:51","pubTimestamp":1792759908,"startTime":"0","endTime":"0","summary":"证券之星消息,海南海药(000566)10月22日在投资者关系平台上答复投资者关心的问题。投资者提问:尊敬的董秘你好,氟非尼酮二期临床已经结束,三期已经启动招募,请问公司基于什么样的考虑不披露二期揭盲数据?海南海药回复:尊敬的投资者您好!公司抗肝纤维化1类新药氟非尼酮胶囊III期临床研究正在积极有序推进,如涉及需履行信息披露义务的事项,公司将严格按照相关法律法规的要求履行。感谢您对公司的关注!本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。责任编辑:刘浩然","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102300042260.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","000566","BK0060","BK0188","BK0239","BK0146"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677922082","title":"海南海药:相关技术指导原则的制定有助于进一步规范慢性乙型肝炎肝纤维化治疗药物的临床试验设计与评价标准","url":"https://stock-news.laohu8.com/highlight/detail?id=2677922082","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677922082?lang=zh_cn&edition=full","pubTime":"2026-10-23 20:51","pubTimestamp":1792759907,"startTime":"0","endTime":"0","summary":"证券之星消息,海南海药10月22日在投资者关系平台上答复投资者关心的问题。投资者提问:尊敬的董秘,2026年9月22日,国家药监局药审中心发布通知,就《慢性乙型肝炎肝纤维化治疗药物临床试验技术指导原则》公开征求意见。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102300042258.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","000566","BK0146","BK0188","BK0239","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677220999","title":"海南海药:氟非尼酮进展情况请以CDE官网公示信息为准","url":"https://stock-news.laohu8.com/highlight/detail?id=2677220999","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677220999?lang=zh_cn&edition=full","pubTime":"2026-10-23 20:51","pubTimestamp":1792759907,"startTime":"0","endTime":"0","summary":"证券之星消息,海南海药(000566)10月22日在投资者关系平台上答复投资者关心的问题。投资者提问:尊敬的董秘,贵公司氟非尼酮三期已经首例患者入组,这一里程碑事件,威哥贵公司CDE状态关键字节一直迟迟不更新?海南海药回复:尊敬的投资者您好!氟非尼酮进展情况请以国家药品监督管理局药品审评中心(CDE)官方网站\"药物临床试验登记与信息公示平台\"公布的信息为准。感谢您对公司的关注!本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。责任编辑:刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102300042257.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0188","BK0239","000566","BK0070","BK0146"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677922724","title":"海南海药:存款利率不低于央行同期同类存款利率","url":"https://stock-news.laohu8.com/highlight/detail?id=2677922724","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677922724?lang=zh_cn&edition=full","pubTime":"2026-10-23 20:51","pubTimestamp":1792759899,"startTime":"0","endTime":"0","summary":"证券之星消息,海南海药10月22日在投资者关系平台上答复投资者关心的问题。这一部分会给亏损的海南海药减免吗?请详细说明,谢谢!感谢您对公司的关注!本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102300042250.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","000566","ZFmain","BK0239","ZTmain","BK0070","TNmain","BK0146","UBmain","ZBmain","ZNmain","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677922723","title":"海南海药:积极寻找转型发展,把改革调整作为破解困局的关键举措","url":"https://stock-news.laohu8.com/highlight/detail?id=2677922723","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677922723?lang=zh_cn&edition=full","pubTime":"2026-10-23 20:51","pubTimestamp":1792759879,"startTime":"0","endTime":"0","summary":"证券之星消息,海南海药10月22日在投资者关系平台上答复投资者关心的问题。对于公司目前净资产为负的窘境,公司目前从哪些方面考虑垫厚净资产问题,有没有可推进落地的项目?公司正在努力提升经营业绩为股东创造价值。感谢您对公司的关注!本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102300042233.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0146","000566","BK0060","BK0070","BK0188","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674847513","title":"海南海药(000566)10月9日主力资金净买入890.45万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2674847513","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674847513?lang=zh_cn&edition=full","pubTime":"2026-10-12 09:10","pubTimestamp":1791767427,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2026年10月9日收盘,海南海药报收于4.71元,上涨3.97%,换手率6.56%,成交量85.0万手,成交额3.9亿元。近5日资金流向一览见下表:海南海药融资融券信息显示,融资方面,当日融资买入937.1万元,融资偿还1174.71万元,融资净偿还237.61万元。海南海药主营业务:围绕大健康布局,涵盖中间体、原料药、化学制剂、现代中药及医疗服务等领域,目前以药品研发、生产和销售为主。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101200002966.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0146","BK0239","BK0070","BK0188","000566","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674845953","title":"股市必读:海南海药新发布《关于子公司获得注射用硫酸艾沙康唑药品注册批件的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2674845953","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674845953?lang=zh_cn&edition=full","pubTime":"2026-10-12 02:16","pubTimestamp":1791742571,"startTime":"0","endTime":"0","summary":"公司公告汇总关于子公司获得注射用硫酸艾沙康唑药品注册批件的公告近日,海南海药股份有限公司全资子公司海口市制药厂有限公司获得国家药品监督管理局核准签发的化学药品“注射用硫酸艾沙康唑”的《药品注册证书》。该药品适用于治疗成人和1岁及以上儿童患者的侵袭性曲霉病、侵袭性毛霉病。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101200000743.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0239","000566","BK0146","BK0060","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674851121","title":"海南海药最新公告:子公司获注射用硫酸艾沙康唑药品注册批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2674851121","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674851121?lang=zh_cn&edition=full","pubTime":"2026-10-09 20:17","pubTimestamp":1791548273,"startTime":"0","endTime":"0","summary":"海南海药(000566.SZ)公告称,公司全资子公司海口市制药厂获国家药监局核准签发的注射用硫酸艾沙康唑《药品注册证书》。该药品适用于治疗成人和1岁及以上儿童患者的侵袭性曲霉病、侵袭性毛霉病。以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100900034417.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0146","BK0239","000566","BK0188","BK0060","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669430282","title":"海南海药(000566)9月23日主力资金净卖出2017.26万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2669430282","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669430282?lang=zh_cn&edition=full","pubTime":"2026-09-24 09:17","pubTimestamp":1790212658,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2026年9月23日收盘,海南海药报收于4.8元,下跌3.61%,换手率6.21%,成交量80.58万手,成交额3.92亿元。近5日资金流向一览见下表:海南海药融资融券信息显示,融资方面,当日融资买入1388.92万元,融资偿还1390.78万元,融资净偿还1.86万元。海南海药主营业务:围绕大健康布局,涵盖中间体、原料药、化学制剂、现代中药及医疗服务等领域,目前以药品研发、生产和销售为主。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092400009191.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0146","BK0060","BK0239","000566","BK0188","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669316191","title":"异动快报:海南海药(000566)9月21日10点54分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2669316191","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669316191?lang=zh_cn&edition=full","pubTime":"2026-09-21 10:55","pubTimestamp":1789959326,"startTime":"0","endTime":"0","summary":"证券之星9月21日盘中消息,10点54分海南海药(000566)触及涨停板。其所属行业化学制药目前上涨。领涨股为华仁药业。该股为创新药,CAR-T疗法,医药概念热股,当日创新药概念上涨4.55%,CAR-T疗法概念上涨4.18%,医药概念上涨3.9%。9月18日的资金流向数据方面,主力资金净流出1504.86万元,占总成交额6.65%,游资资金净流入791.97万元,占总成交额3.5%,散户资金净流入712.89万元,占总成交额3.15%。近5日资金流向一览见下表:海南海药主要指标及行业内排名如下:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092100007626.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","000566","BK0070","BK0239","BK0146","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667365986","title":"海南海药最新公告:销售代理合同纠纷案原告撤诉","url":"https://stock-news.laohu8.com/highlight/detail?id=2667365986","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667365986?lang=zh_cn&edition=full","pubTime":"2026-09-16 21:10","pubTimestamp":1789564253,"startTime":"0","endTime":"0","summary":"海南海药(000566.SZ)公告称,公司收到海口市秀英区人民法院《民事裁定书》,原告陈光华、文瑞就销售代理合同纠纷案提出撤诉申请,法院裁定准许撤诉。该诉讼案件已了结,不会对公司本期利润或期后利润产生重大影响。截至公告披露日,公司尚未结案的诉讼、仲裁案件涉及金额总计约1.16亿元,占最近一期经审计净资产的97.04%。以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091600035922.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","000566","BK0146","BK0188","BK0239","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666226025","title":"海南海药:氟非尼酮胶囊正在开展III期临床研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2666226025","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666226025?lang=zh_cn&edition=full","pubTime":"2026-09-11 20:52","pubTimestamp":1789131135,"startTime":"0","endTime":"0","summary":"证券之星消息,海南海药(000566)09月10日在投资者关系平台上答复投资者关心的问题。投资者提问:请问至8月30日,股东人数多少?两款创新药进展如何?氟非尼酮三期入组了吗海南海药回复:尊敬的投资者您好!公司根据规定在定期报告中披露相关股东人数,敬请查阅已经披露的定期报告并关注后续披露的定期报告。派恩加滨片正在开展IIb期临床研究。氟非尼酮胶囊正在开展III期临床研究,入组情况请关注CDE药物临床试验登记与信息公示平台的信息。公司如有达到信息披露标准的新进展,将根据规定及时履行信息披露义务。感谢您对公司的关注!本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。责任编辑:刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091100047601.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0146","BK0239","000566","BK0188","BK0060","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666522670","title":"海南海药:紧盯创新药核心突破","url":"https://stock-news.laohu8.com/highlight/detail?id=2666522670","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666522670?lang=zh_cn&edition=full","pubTime":"2026-09-11 20:52","pubTimestamp":1789131125,"startTime":"0","endTime":"0","summary":"证券之星消息,海南海药09月10日在投资者关系平台上答复投资者关心的问题。投资者提问:尊敬的董秘,贵公司半年报后净资产已经为负,营收连年下滑,扣非9年亏损,生存困难。氟非尼酮目前进入关键III期验证,派恩加滨IIB期,HY-001临床前期。创新药烧钱,贵公司资金短缺,为何不砍掉或者出售创新药管线,全力保壳?本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091100047590.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","BK0239","06978","BK0070","159992","BK0060","BK1574","000566","BK0188","BK0146"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666522962","title":"海南海药:符合资本化条件的研发项目按会计准则资本化","url":"https://stock-news.laohu8.com/highlight/detail?id=2666522962","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666522962?lang=zh_cn&edition=full","pubTime":"2026-09-11 20:52","pubTimestamp":1789131124,"startTime":"0","endTime":"0","summary":"证券之星消息,海南海药(000566)09月10日在投资者关系平台上答复投资者关心的问题。投资者提问:尊敬的董秘,派恩加滨IIB期伦理会已于8月7日由首都医科大学附属北京天坛医院医学伦理委员会批准过会,CDE已经公示IIB期方案,请问IIB期的研发投入是否可以资本化处理?海南海药回复:尊敬的投资者您好!公司对于符合资本化条件的研发项目,根据会计准则要求进行资本化处理,资本化投入不影响当期损益。具体情况请以公司定期报告及公开披露信息为准。感谢您对公司的关注!本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。责任编辑:刘浩然","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091100047587.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0146","000566","BK0060","BK0070","BK0188","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1795186124221,"stockEarnings":[{"period":"1week","weight":-0.0988},{"period":"1month","weight":-0.1351},{"period":"3month","weight":-0.2459},{"period":"6month","weight":-0.1472},{"period":"1year","weight":-0.4931},{"period":"ytd","weight":-0.4895}],"compareEarnings":[{"period":"1week","weight":-0.0214},{"period":"1month","weight":-0.0422},{"period":"3month","weight":-0.0839},{"period":"6month","weight":-0.1301},{"period":"1year","weight":-0.0935},{"period":"ytd","weight":-0.0986}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"海南海药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"141182人(较上一季度增加11.48%)","perCapita":"9184股","listingDate":"1994-05-25","address":"海南省海口市秀英区南海大道192号","registeredCapital":"129736万元","survey":" 海南海药股份有限公司的主营业务是药品研发、生产和销售。公司的主要产品是抗生素系列、胃肠道用药系列、抗肿瘤药系列、与制剂配套的原料药和中间体系列。","listedPrice":5.8},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.54.0","shortVersion":"4.54.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"海南海药(000566)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供海南海药(000566)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"海南海药,000566,海南海药股票,海南海药股票老虎,海南海药股票老虎国际,海南海药行情,海南海药股票行情,海南海药股价,海南海药股市,海南海药股票价格,海南海药股票交易,海南海药股票购买,海南海药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"海南海药(000566)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供海南海药(000566)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}